Ruperto, Nicolino <br/><br/>
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.  [electronic resource] 

 -  Arthritis and rheumatism  Feb 2012 
 - 557-67 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1529-0131 
<br/><br/><label>Standard No.: </label>10.1002/art.33342  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antirheumatic Agents--administration & dosage<br/>Arthritis, Juvenile--drug therapy<br/>Child<br/>Child, Preschool<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Interleukin-1beta--antagonists & inhibitors<br/>Male<br/>Treatment Outcome<br/>Young Adult